First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma

被引：1
|
作者：
Tsimafeyeu, Ilya [1 ]
Tjulandin, Sergei [1 ]
机构：
[1] Russian Soc Clin Oncol, Moscow, Russia
来源：
BJU INTERNATIONAL | 2019年 / 123卷 / 04期
关键词：
urothelial carcinoma; atezolizumab; pembrolizumab; cisplatin-ineligible patients; PD-L1; testing; CISPLATIN-INELIGIBLE PATIENTS; SINGLE-ARM; MULTICENTER; ATEZOLIZUMAB; CHEMOTHERAPY;
D O I：
10.1111/bju.14627
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：563 / 565
页数：3
相关论文
共 50 条
  • [1] First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin
    Iacovelli, R.
    Ciccarese, C.
    Brunelli, M.
    Battelli, N.
    Buttigliero, C.
    Caserta, C.
    Buti, S.
    Santini, D.
    Carella, C.
    Galli, L.
    Verri, E.
    Ermacora, P.
    Merler, S.
    Masini, C.
    De Vivo, R.
    Milesi, L.
    Spina, F.
    Rizzo, M.
    Sperduti, I.
    Fornarini, G.
    Tortora, G.
    ANNALS OF ONCOLOGY, 2022, 33 (11) : 1179 - 1185
  • [2] Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma
    Guo, Lifang
    Wang, Xin
    Wang, Shihui
    Hua, Linbin
    Song, Nan
    Hu, Bin
    Tong, Zhaohui
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [3] The efficacy and safety of chemotherapy with or without anti-PD-1 for the first-line treatment of advanced urothelial carcinoma
    Han, Fuxin
    Wu, Zhaozhen
    Chen, Jiaxin
    Liu, Meicen
    Hu, Yi
    CANCER MEDICINE, 2023, 12 (23): : 21129 - 21137
  • [4] Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors
    Pond, Gregory R.
    Agarwal, Archana
    Ornstein, Moshe
    Garcia, Jorge
    Gupta, Ruby
    Grivas, Petros
    Drakaki, Alexandra
    Lee, Jae-Lyun
    Kanesvaran, Ravindran
    Di Lorenzo, Giuseppe
    Verolino, Pasquale
    Barata, Pedro
    Bilen, Mehmet A.
    Hussain, Syed A.
    Curran, Catherine
    Sonpavde, Guru
    CLINICAL GENITOURINARY CANCER, 2021, 19 (05) : 425 - 433
  • [5] Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors
    Maiorano, Brigida Anna
    Di Maio, Massimo
    Cerbone, Linda
    Maiello, Evaristo
    Procopio, Giuseppe
    Roviello, Giandomenico
    JAMA NETWORK OPEN, 2024, 7 (03) : E241215
  • [6] Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors
    Mota, Jose Mauricio
    Teo, Min Yuen
    Whiting, Karissa
    Li, Han A.
    Regazzi, Ashely M.
    Lee, Chung-Han
    Funt, Samuel A.
    Bajorin, Dean
    Ostrovnaya, Irina
    Iyer, Gopa
    Rosenberg, Jonathan E.
    JOURNAL OF IMMUNOTHERAPY, 2021, 44 (07) : 248 - 253
  • [7] First-line immune checkpoint inhibitors for patients with metastatic urothelial carcinoma treated in routine clinical practice
    Naito, Renato
    Izumi, Kouji
    Mizokami, Atsushi
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 (03) : 986 - 990
  • [8] The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
    Houssiau, Helene
    Seront, Emmanuel
    CANCERS, 2022, 14 (07)
  • [9] Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma
    Tang, Bixia
    Xiao, Jun
    Chi, Zhihong
    Duan, Rong
    Cui, Chuanliang
    Si, Lu
    Liu, Yixun
    Hu, Xuechun
    Liu, Zhi
    Xiang, Ping
    Li, Siming
    Yan, Xieqiao
    Zhou, Li
    Li, Juan
    Li, Yujie
    Yu, Xiaohui
    Dai, Xiangrong
    Li, Xiaoyi
    Guo, Jun
    Sheng, Xinan
    ONCOLOGIST, 2024,
  • [10] PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis
    Ghate, Ketan
    Amir, Eitan
    Kuksis, Markus
    Hernandez-Barajas, David
    Rodriguez-Romo, Laura
    Booth, Christopher M.
    Vera-Badillo, Francisco E.
    CANCER TREATMENT REVIEWS, 2019, 76 : 51 - 56
12345